Several analysts have recently updated their ratings and price targets for Karyopharm Therapeutics (NASDAQ: KPTI):

  • 3/2/2019 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 3/1/2019 – Karyopharm Therapeutics was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $7.00 price target on the stock, down previously from $21.00.
  • 2/27/2019 – Karyopharm Therapeutics was downgraded by analysts at Bank of America Corp from a “neutral” rating to an “underperform” rating. They now have a $5.00 price target on the stock, down previously from $15.00.
  • 2/27/2019 – Karyopharm Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 2/27/2019 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and an estimated early stage pipeline value of $0.86/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x.””
  • 2/25/2019 – Karyopharm Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 2/25/2019 – Karyopharm Therapeutics had its price target lowered by analysts at Wedbush from $19.00 to $14.00. They now have an “outperform” rating on the stock.
  • 2/14/2019 – Karyopharm Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 2/7/2019 – Karyopharm Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 2/2/2019 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 1/31/2019 – Karyopharm Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/16/2019 – Karyopharm Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/15/2019 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Shares of NASDAQ:KPTI traded down $0.02 during trading on Thursday, reaching $4.40. The company had a trading volume of 676,589 shares, compared to its average volume of 1,633,718. The company has a current ratio of 7.13, a quick ratio of 7.13 and a debt-to-equity ratio of 0.56. Karyopharm Therapeutics Inc has a fifty-two week low of $3.92 and a fifty-two week high of $21.71. The firm has a market cap of $276.30 million, a P/E ratio of -1.40 and a beta of 3.18.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, February 28th. The company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.87) by ($0.09). Karyopharm Therapeutics had a negative net margin of 588.10% and a negative return on equity of 107.60%. Research analysts forecast that Karyopharm Therapeutics Inc will post -3.56 EPS for the current fiscal year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 1,481,643 shares of the business’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $4.81, for a total transaction of $7,126,702.83. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $10.23, for a total value of $127,875.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,294,143 shares of company stock worth $11,246,578. Company insiders own 13.26% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 660.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock worth $36,000 after acquiring an additional 3,300 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Karyopharm Therapeutics by 197.4% in the fourth quarter. IFP Advisors Inc now owns 5,650 shares of the company’s stock worth $52,000 after acquiring an additional 3,750 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Karyopharm Therapeutics by 31.3% in the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after acquiring an additional 2,411 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Karyopharm Therapeutics in the third quarter worth $195,000. Finally, Verition Fund Management LLC acquired a new position in shares of Karyopharm Therapeutics in the third quarter worth $242,000. Institutional investors own 84.81% of the company’s stock.

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Featured Story: Why is Cost of Capital Important?

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.